Alnylam Pharmaceuticals, Inc
Price
OptionsOpen the Sheet →FilingsNewest: 10-Q, Quarterly reportJul 30 →InsidersNo open-market buys. 7 insiders sold $43.6M, 136 of 278 sales on a 10b5-1 plan.→HoldersFMR 11.2%Capital World Investors 8.3%BlackRock 8.2%→Financing →PeersClosest companies: ARWR, BBIO, RIGL→
From the filings
Figures
- Revenue
- $4.80Blast 12 months
- Net income
- $733.1Mlast 12 months
- Operating cash flow
- $714.9Mlast 12 months
- Cash and equivalents
- $1.71Bat the last balance sheet
- Shares outstanding
- 133.7M shareson issue